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Abstract. Serum cobalamin and folate are often measured in cats and dogs as part of laboratory 16 
testing for intestinal disease, small intestinal dysbiosis, or exocrine pancreatic deficiency. We 17 
performed an analytical validation of human immunoassays for cobalamin and folate 18 
measurement (AIA-900 analyzer, Tosoh Bioscience) and compared results with those obtained 19 
using chemiluminescence assays (Immulite 2000 analyzer, Siemens Medical Solutions 20 
Diagnostics). Accuracy, precision, total observable error (TEobs%), and σ values were calculated 21 
for the immunoassays. Correlation and agreement were evaluated with Deming regression, 22 
Passing–Bablok regression, and Bland–Altman analysis. Cobalamin intra-assay and inter-assay 23 
CVs were 1.8–9.3% and 2.6–6.8%, respectively. Folate intra-assay and inter-assay CVs were 24 
1.5–9.1% and 3.4–8.1%, respectively. TEobs (%) were ≤19 and ≤31 for cobalamin and folate, 25 
respectively. Sigma values were 3.60–11.50 for cobalamin and 2.90–7.50 for folate. Regression 26 
analysis demonstrated very high or high correlations for cobalamin [r = 0.98 (dogs), 0.97 (cats)] 27 
and folate [r = 0.88 (dogs), 0.92 (cats)] but Bland–Altman analysis revealed poor agreement for 28 
both. The immunoassays had good analytical performance for measuring cobalamin and folate in 29 
both species. Results obtained by the 2 analyzers cannot be used interchangeably and should be 30 
interpreted using instrument-specific reference intervals. Further studies are required to establish 31 
immunoassay-specific reference intervals and to evaluate the diagnostic performance and clinical 32 
utility of the analyzer for these analytes. 33 
 34 
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Introduction 37 
Serum cobalamin and folate are commonly measured in cats and dogs as part of laboratory 38 
testing, primarily for the diagnosis of intestinal disease, small intestinal dysbiosis, or exocrine 39 
pancreatic deficiency.6 Cobalamin (vitamin B12) is absorbed through specialized receptors in the 40 
ileum after binding to intrinsic factor (IF). IF is synthesized by the pancreas in cats,19 and the 41 
stomach, pancreas, and salivary glands in dogs.4,44 Cobalamin acts as a cofactor for several 42 
enzymatic systems in mammals and plays an important role in the synthesis of amino acids and 43 
DNA.6,10 Diseases affecting the distal small intestine, the production of IF (e.g., exocrine 44 
pancreatic insufficiency) or the metabolism of cobalamin by bacteria (e.g., small intestinal 45 
dysbiosis), as well as certain metabolic diseases (e.g., feline hyperthyroidism) have been 46 
associated with decreased serum cobalamin concentrations.8,10 Folate (vitamin B9) is absorbed 47 
via specific carriers in the proximal small intestine and has major functions in the transfer of one-48 
carbon units in several biosynthetic pathways involved in DNA and amino acid synthesis and 49 
cellular metabolism.35 Decreased serum levels reflect proximal small intestinal disease, whereas 50 
increased concentrations can be associated with small intestinal dysbiosis, given that folate can 51 
be synthesized by bacteria.6 52 
In the human field, several commercial immunoassays are available for the measurement 53 
of cobalamin and folate; validation and method comparison studies have demonstrated these 54 
assays to have acceptable levels of precision, with good-to-moderate correlation but poor 55 
agreement between different methods.30,39 However, in veterinary medicine, analytical validation 56 
studies of cobalamin and folate assays are not only sparse5,22,43 but all available publications 57 
utilize the same human chemiluminescence immunoassays (Immulite, Siemens Healthineers, 58 
Erlangen, Germany).3,8,22,43 Although the publication of more in-depth validation studies on the 59 
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chemiluminescent immunoassays would be welcome, these assays have been widely accepted as 60 
having acceptable linearity, recovery, and precision. Published studies tend to corroborate 61 
precision data provided by the manufacturer [cobalamin CVs intra-assay: 13%, 7%, and 6.7%; 62 
inter-assay: 15%, 6%, and 7.9%; folate CVs intra-assay: 6.9%, 4.1%, and 2.4%; inter-assay: 63 
8.8%, 5.7%, and 5.2%; each for low-, medium-, and high-quality control material (QCM), 64 
respectively]. However, no studies have reported total observed error (TEobs) values or utilized 65 
sigma (σ) metrics to evaluate the performance of these methods for veterinary use, to our 66 
knowledge. 67 
The evaluation of total error and sigma metrics are accepted as part of quality control 68 
monitoring in human medical laboratories, and also as adjuncts to classic analytical validation 69 
studies.32,48,50 By quantifying the analytical performance of a method and comparing it to preset 70 
analytical quality specifications [total allowable error (TEa)], the quality of an analytical process 71 
can be evaluated objectively based on performance goals. In the context of immunoassays, these 72 
techniques are used and recommended in many human validation studies.14,25,37,45,51 Although not 73 
frequent elements of veterinary analytical validation studies, incorporation of these methods has 74 
been recommended,23,32 and they feature in several publications assessing the performance of 75 
veterinary biochemistry analyzers.13,27 76 
Among the immunoassay analyzers available for use in human patients is the AIA-900 77 
(Tosoh Bioscience, Tokyo, Japan), which can measure a variety of analytes,7,53 including serum 78 
cobalamin and folate. Three human Tosoh assays, namely thyroxine (T4), cortisol, and 79 
adrenocorticotropic hormone (ACTH), have been validated and are available for use in dogs, 80 
cats, and horses.26,29 81 
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We evaluated the accuracy, precision, TEobs, and σ values of the Tosoh immunoassays for 82 
measuring cobalamin and folate and compared the Tosoh results with those obtained by the 83 
Immulite chemiluminescence assays that are used routinely in dogs and cats. 84 
Materials and methods 85 
Our study took place at Langford Diagnostic Laboratories (Bristol, UK) between December 2015 86 
and April 2017 after approval of the study protocol by the Animal Welfare and Ethical Review 87 
Board of the University of Bristol (VIN/17/040). 88 
Immunoassays 89 
Tosoh 90 
Cobalamin and folate were measured in our laboratory on the AIA-900 analyzer (Tosoh 91 
Bioscience), which utilizes 2-site immunoenzymometric assays for serum. For cobalamin 92 
measurement, the serum sample is automatically pre-treated with dithiothreitol, sodium 93 
hydroxide, and potassium cyanide. This releases cyanocobalamin from serum-binding proteins, 94 
converting it into a stable, measurable form. Serum is placed in a test cup containing magnetic 95 
beads coated with murine monoclonal anti-fluorescein antibody. A set amount of porcine 96 
fluorescein-labeled IF and alkaline phosphatase–labeled cobalamin are added to the sample and 97 
incubated. During this time, the patient’s cobalamin competes with the labeled cobalamin for 98 
binding to fluorescein-labeled IF. The latter binds to the magnetic beads, which are then washed 99 
to remove any unbound cobalamin. The beads are incubated with a fluorogenic substance (4-100 
methylumbelliferyl phosphate), which reacts with alkaline phosphatase, and the resulting 101 
fluorescence is measured. The amount of cobalamin in the patient sample is inversely 102 
proportional to the labeled cobalamin and can be calculated using concentration curves based on 103 
known amounts of labeled cobalamin. The measurement of folate uses the same principle and 104 
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antibody type, except that the IF is replaced by a bovine folate-binding protein. Calibration, daily 105 
checks, and maintenance procedures were carried out as described by the manufacturer 106 
(Operator's manual, automated enzyme immunoassay analyzer AIA-2000, AIA-360, AIA-900, 107 
AIA-600II, AIA-1800, CD-ROM, 2013; Tosoh Europe, Tessenderlo, Belgium). Daily checks 108 
included analyzing in duplicate the 3 manufacturer-supplied human QCM at 3 different 109 
concentration levels (QCMLow, QCMMedium, QCMHigh). A sample volume of 200 μL (cobalamin) 110 
and 160 µL (folate) was required. The manufacturer’s working ranges were 37–1,480 pmol/L for 111 
serum cobalamin and 1.1–45.3 nmol/L for serum folate concentrations. 112 
Immulite 113 
Cobalamin and folate were measured at an external referral veterinary laboratory (Axiom 114 
Veterinary Laboratories, Newtown Abbott, UK) on the Immulite 2000 analyzer (Siemens 115 
Medical Solutions Diagnostics, Flanders, NJ), which employs a solid-phase, 2-site, sequential 116 
chemiluminescent immunometric assay. The assay can be performed on serum or heparinized 117 
plasma but only serum was used in our study. 118 
For cobalamin analysis, the serum or plasma sample is automatically pre-treated with 119 
dithiothreitol, sodium hydroxide, and potassium cyanide to release cobalamin from binding 120 
proteins and inactivate the binding proteins. The serum is then transferred to a test unit, which 121 
contains a cobalamin-coated polystyrene bead and a set amount of porcine IF, and the test unit is 122 
incubated. During this time, the patient’s cobalamin competes with the bead-bound cobalamin 123 
for binding to IF. Alkaline phosphatase–labeled murine monoclonal anti-porcine IF antibody is 124 
then added, which binds to IF, and any unbound cobalamin is washed off from the beads. A 125 
chemiluminescent substrate is added and hydrolyzed in the presence of alkaline phosphatase, 126 
resulting in production of a chemiluminescent agent. The amount of light emitted reflects the 127 
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amount of bound cobalamin and is inversely proportional to the amount in the patient’s sample. 128 
The folate assay uses the same principle and antibody type, except that the IF is replaced by 129 
folate-binding protein. The Immulite required a sample volume of 75 µL and 50 µL for 130 
cobalamin and folate measurement, respectively. The manufacturer’s working ranges for these 131 
immunoassays were 110–740 pmol/L for serum cobalamin and 2–54 nmol/L for serum folate 132 
concentrations. 133 
Internal precision data supplied by the external referral laboratory performing the 134 
Immulite assays indicated inter-assay CVs of 5.8%, 5.5%, and 7.8% for cobalamin, and 8.7%, 135 
7.6%, and 8.3% for folate, for low, medium, and high QCM, respectively (Skeldon N, Axiom 136 
Laboratories, pers. comm., 10 July 2018). Reference intervals (RIs) established at the external 137 
referral laboratory were 200–400 pmol/L and 220–500 pmol/L for canine and feline cobalamin, 138 
respectively, and 12–30 nmol/L and 19–37 nmol/L for canine and feline folate, respectively. 139 
Sample selection and handling 140 
Analytical validation 141 
For the analytical validation of the Tosoh immunoassays, 3 manufacturer-supplied human QCM, 142 
3 canine (CPLow, CPMedium, CPHigh), and 3 feline (FPLow, FPMedium, FPHigh) pooled serum samples 143 
were used. The QCM were reconstituted according to the manufacturer’s instructions (AIA-pack 144 
multi analyte control MAC kit insert, Tosoh Europe). Reconstituted QCM remains stable for 7 d 145 
at 2–8°C and up to 4 wk frozen at –20°C. 146 
Pooled samples were created by mixing surplus serum from clinical samples submitted to 147 
our laboratory. Owner consent had been obtained at the time of blood sampling for use of surplus 148 
serum for research purposes. During investigation of the clinical cases, venous blood samples 149 
(2–3 mL) were collected and stored in plain tubes. Following clot retraction and centrifugation 150 
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(1,751 × g for 5 min), serum was withdrawn from the tubes, used for biochemical assays 151 
requested by the clinician, and then the surplus serum was stored in plain tubes at –20°C. To 152 
select stored samples for the creation of the serum pools, a retrospective database search 153 
identified canine and feline clinical samples tested for cobalamin and folate between December 154 
2015 and April 2016 at the external referral laboratory with the Immulite immunoassays. The 155 
selected serum samples had been stored at –20°C for up to 6 mo, and were thawed at room 156 
temperature for pooling. The pools were then frozen at –20°C in aliquots of 300 μL. 157 
Method comparison 158 
We used canine and feline serum samples submitted to our laboratory between May 2016 and 159 
April 2017. Samples from clinical cases were utilized to generate a wide range of values in order 160 
to provide more accurate information regarding the degree of correlation and agreement between 161 
the 2 analyzers.32 The animals showed a variety of clinical signs, and all had been referred to 162 
Langford Small Animal Referral Hospital (Bristol, UK) for further investigation of their 163 
illnesses. Clinical samples were included in the study when sufficient surplus serum was deemed 164 
available for analysis. All samples were split into 2 aliquots of 500 µL. One aliquot was sent by 165 
overnight courier to the external referral laboratory and the other was refrigerated at 4°C. The 166 
following day, serum cobalamin and folate concentrations were measured at the external referral 167 
laboratory by the Immulite 2000 (CobalaminImmulite, FolateImmulite) and at our facility with the 168 
Tosoh AIA-900 (CobalaminTosoh, FolateTosoh). 169 
Analytical validation 170 
Analytical validation of both the cobalamin and folate Tosoh immunoassays included the 171 
determination of accuracy and precision.16,17,23,32 172 
Accuracy 173 
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Accuracy was assessed by performing linearity (dilutional parallelism) and spiking-recovery 174 
studies. Linearity was determined by serial dilution of the CPHigh and FPHigh samples using 175 
diluent buffer (AIA-pack B12 and AIA-pack folate sample diluting solution, Tosoh Europe). 176 
Specifically, 6 levels of dilution were tested, with dilution factors ranging from 1 (neat serum) to 177 
28 based on respective serum-to-buffer volumes in microliters of 400/0, 300/100, 200/200, 178 
100/300, 50/350, etc. Neat and diluted samples were then measured once sequentially within the 179 
same assay run. A curve representing the measured versus expected cobalamin or folate 180 
concentration was constructed. Three or 4 replicate samples for each dilution are recommended 181 
to avoid false rejection of a method, but if linearity can be demonstrated using single 182 
measurements, it is sufficient for analysis.15,48 183 
The spiking-recovery study was performed by mixing the serum pools (PHigh + PMedium, 184 
PHigh + PLow, PMedium + PLow) and measuring these mixed samples sequentially within the same 185 
assay run. Measured and expected cobalamin and folate concentrations for each diluted sample 186 
were then compared and the recovery percentages calculated. 187 
Precision 188 
Precision was assessed by evaluating the intra- and inter-assay variability using the 3 QCM, and 189 
the 3 canine and feline serum pools. Intra-assay variability (repeatability) was determined by 190 
measuring cobalamin and folate in the same sample 10–13 times sequentially within a single run. 191 
Inter-assay variability (reproducibility) was determined by analyzing the same sample in 192 
duplicate once on 15 consecutive working days. 193 
Quality requirements 194 
The analytical performance of the Tosoh assays was assessed by calculating TEobs(%) and σ 195 
values. TEobs(%) was determined by the following formula: TEobs(%) = 2 × CV + bias (%).
23 196 
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Bias was calculated using the formula: bias (%) = [(target – measured) ÷ target] × 100%, wherein 197 
“target” is the mean analyte concentration reported by the manufacturer, and “measured” is the 198 
mean analyte concentration measured by the Tosoh over a 15-d period.16 199 
TEobs(%) was determined for the QCM and serum pools, as follows. For each QCM, 200 
TEobs(%) was calculated using the inter-assay CV and bias (%) for QCMLow, QCMMedium, and 201 
QCMHigh, respectively. For each pool, TEobs(%) was calculated using the inter-assay CV for the 202 
respective species pools and the bias(%) derived from the QCMLow, QCMMedium, or QCMHigh (for 203 
the low, medium, and high pools, respectively). 204 
Sigma values for each QCM and each serum pool were calculated using the formula: σ = 205 
[TEa (%) – bias (%)] ÷ CV.42,48 The bias and inter-assay CV used were as defined above. 206 
Because TEa is not available for dogs or cats, the TEa (%) employed in human studies 207 
(cobalamin: 30%; folate: 39%) were used (Desirable biological variation database specifications, 208 
2014. Available from https://www.westgard.com/biodatabase1.htm, accessed 2018.11.17). A 209 
method was considered acceptable if TEobs < TEa.
23 Interpretation of the σ values was performed 210 
as follows: >2: poor, >3: marginal, >4: good, >5: excellent, and >6: world class.38,49 A 6-sigma 211 
result indicates that a process is nearly defect-free, with <4 defects per million outcomes; 3-212 
sigma is considered the minimally acceptable performance level of an analytical process, 213 
equivalent to ~67,000 defects per million outcomes.50 214 
Statistical analysis 215 
Data were recorded (Excel 2016, Microsoft, Redmond, WA) and analyzed (Prism 4 software, 216 
GraphPad, La Jolla, CA). For clinical samples generating results beyond the lower (<L) or upper 217 
(>H) limits of detection, the value that was used for statistical analysis was calculated by 218 
subtracting 1 pmol/L (cobalamin) or 1 nmol/L (folate) from the lowest measurable limit, and by 219 
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adding 1 pmol/L or 1 nmol/L to the highest measurable limit, as performed in another study.40 220 
Normal distribution was evaluated using the D’Agostino and Pearson omnibus normality test. 221 
Statistical significance was set at p ≤ 0.05. 222 
Linearity (dilutional parallelism) was evaluated by plotting the measured against the 223 
expected concentrations and determining the slope and intercept using simple linear regression. 224 
Inter- and intra-assay variability were expressed as the CV following calculation of the mean and 225 
SD for each set of results. 226 
Correlations for the method comparison (Tosoh vs. Immulite) were selected based on 227 
parametric or nonparametric data distribution (Pearson and Spearman correlations, respectively). 228 
Correlation coefficients were interpreted as 0.90–1.00: very high correlation, 0.70–0.89: high 229 
correlation, 0.50–0.69: moderate correlation, 0.30–0.49: low correlation, and <0.30: little, if any, 230 
correlation (Zady M. Z-12: correlation and simple least square regression, 2000. Available from 231 
https://www.westgard.com/lesson42.htm, accessed 2018.11.17). Following published 232 
recommendations,32 r values were used as a guide for selection of appropriate regression 233 
analysis. Deming or Passing–Bablok regression analysis was selected for parametric and 234 
nonparametric data, respectively. Although the correlation and regression analysis help to 235 
determine the association between 2 methods, Bland–Altman analysis is regarded as a more 236 
robust means to assess agreement.1,20 Bland–Altman plots were generated to assess the degree of 237 
agreement between the 2 analyzers (Tosoh vs. Immulite). Agreement was considered good when 238 
there was no real bias or the bias (mean of the differences, Tosoh minus Immulite) was 239 
subjectively small, the 95% confidence intervals (CIs) for the bias were subjectively narrow, and 240 
no outliers were present [i.e., values did not fall outside the limits of agreement (mean of 241 
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difference ± 2 SD)].32 No real bias was indicated when the 95% CI for the bias included 242 
zero.1,21,31 243 
Results 244 
Analytical validation 245 
Accuracy 246 
Dilution of the CPHigh and FPHigh samples resulted in linear regression equations with r
2 values of 247 
0.99 and nonsignificant deviation from linearity over the range of diluted samples used in our 248 
study (CobalaminCanine 60–1,050 pmol/L; CobalaminFeline 46–1360 pmol/L; FolateCanine 1.8–26.6 249 
nmol/L; FolateFeline 1.4–39.3 nmol/L). The Tosoh assays demonstrated proportional errors of 250 
0.99–1.03 and constant errors of –6.81 to 14.83 (Figs. 1A–1D). Recoveries of cobalamin were 251 
97–101% for the canine serum pools (mean: 99%) and 95–106% for the feline pools (mean: 252 
100%). Recoveries of folate were 100–102% for the canine pools (mean: 101%) and 96–102% 253 
for the feline pools (mean: 98%; Table 1). 254 
Precision 255 
The mean intra- and inter-assay CV values with low, medium, high QCM and serum pools were 256 
all <10% for the CobalaminTosoh and FolateTosoh assays (Tables 2, 3). 257 
Quality requirements 258 
Bias values for cobalamin QCMLow, QCMMedium, and QCMHigh were 5.4%, –0.6%, and –2.3%, 259 
respectively. For the folate assay, bias values for QCMLow, QCMMedium, and QCMHigh were 260 
15.2%, 7.7%, and 8.5%, respectively. TEobs for cobalamin (range: 4–19%) and folate (range: 17–261 
31%) were all lower than the TEa published in human studies (cobalamin: 30%, folate: 39%). All 262 
σ values for cobalamin were >4, except for the FPLow σ value, which was 3.6 (Table 4). For 263 
folate, all σ values were ≥4, except for the QCMLow σ value, which was 2.9 (Table 4). 264 
Page 13 of 31 
Method comparison 265 
Surplus serum samples from 68 clinical cases (39 dogs, 29 cats) were included in our study, 266 
although for the folate method comparison in dogs, surplus serum from only 37 of the 39 cases 267 
was available. Regarding cobalamin measurements, 6 samples (1 canine, 5 feline) produced 268 
CobalaminTosoh results above the Tosoh assay’s working range. For CobalaminImmulite, 6 (4 269 
canine, 2 feline) and 16 (7 canine, 9 feline) samples generated results below and above the 270 
Immulite assay’s working range, respectively. Regarding folate measurements, 4 samples (1 271 
canine, 3 feline) generated results above the working ranges of both the Tosoh and Immulite. 272 
Correlations (r) between the Tosoh and Immulite results were very high for cobalamin 273 
(dogs: 0.98 and cats: 0.97; both p < 0.001) and folate (0.92; p < 0.001) in cats, and high for folate 274 
in dogs (0.88; p < 0.001; Table 5). Examination of the Bland–Altman plots revealed that there 275 
was large bias for cobalamin (canine: 75 pmol/L, feline: 184 pmol/L) and folate (canine: –1.3 276 
nmol/L, feline: –4.5 nmol/L); the 95% CIs were wide. Seven cobalamin (2 canine, 5 feline) and 3 277 
folate (2 canine, 1 feline) results were identified as outliers (Table 6, Fig. 2). 278 
Discussion 279 
Although we could not find publications comparing the cobalamin and folate assays that we 280 
evaluated in our study, other veterinary validation studies involving Tosoh and Immulite assay 281 
comparisons have reported a high degree of correlation but wide limits of agreement between the 282 
assays.26,29 In the human field, one study comparing Tosoh and Immulite assays for the 283 
measurement of thyroid, fertility, and tumor markers found them to have similar degrees of 284 
precision,53 whereas another publication assessing 4 different analytes demonstrated satisfactory 285 
analytical performance by the Tosoh assays, high levels of correlation, and variable degrees of 286 
agreement with the Immulite.9 287 
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Because commercial reference materials are not available and gold standard methods for 288 
quantifying cobalamin and folate in canine and feline samples do not exist, the accuracy of the 289 
Tosoh assays was assessed indirectly using published linearity (dilutional parallelism) and 290 
spiking-recovery studies.12,22,29 Very high coefficients of determination (r2 > 0.99) were 291 
generated for both analytes in serially diluted samples, with cobalamin and folate recoveries of 292 
95–106% and 96–102%, respectively. These results were not only within recommended ranges 293 
(80–120%, 75–125%)2,47 but also similar to those reported by others using Immulite 294 
immunoassays in pigs (92–123% and 85–115% for cobalamin and folate, respectively)22 and in 295 
cats (96–122% for cobalamin).43 296 
Compared to published studies using Immulite assays, the Tosoh CVs were similar to 297 
those generated for pigs (CVs ≤6.1% and ≤8.7% for cobalamin and folate, respectively)22 and 298 
lower than for cats (cobalamin CV 11.3%).3 Inter-assay CVs were lower than those generated by 299 
the Immulite for pigs (CV ≤9.6% and ≤12.5% for cobalamin and folate, respectively)22 and cats 300 
(cobalamin CV 15.2%).3 In addition, intra- and inter-assay CVs indicated good precision as they 301 
were markedly <15%, the maximum acceptable CV recommended by various bioanalytical 302 
guidelines, demonstrating acceptable repeatability and reproducibility of these assays47 303 
(Guideline on bioanalytical method validation, EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 304 
2, Guidance for the industry: bioanalytical method validation, U.S. Department of Health and 305 
Human Services, FDA, 2001, https://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf). 306 
Acceptability of a method’s analytical performance is ideally determined using preset 307 
analytical quality specifications, such as the TEa, with a method being considered acceptable 308 
when TEobs < TEa.
23 To our knowledge, TEa for cobalamin and/or folate measurement in animals 309 
is not published, although TEa values of 30% for cobalamin and 39% for folate have been 310 
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published for humans (Desirable biological variation database specifications, 2014. Available 311 
from https://www.westgard.com/biodatabase1.htm, accessed 2018.11.17). In our study, the 312 
Tosoh immunoassays were found to be acceptable for measuring low, medium, and high 313 
concentrations of cobalamin and folate (using QCM and serum pools), given that all TEobs were 314 
lower than the published TEa in human medicine. 315 
Using sigma metrics, performance of the CobalaminTosoh method was determined as good 316 
for measuring samples with low concentrations of cobalamin (mean σ: 4.60) and world class for 317 
medium or high concentration samples (mean σ: 10.20 and 8.20, respectively). Performance of 318 
the FolateTosoh assay was good for low concentration serum samples (mean σ: 4.80) and excellent 319 
(mean σ: 5) or world class (mean σ: 18) for samples with medium and high folate concentrations, 320 
respectively. Only one set of results, for the folate QCMLow sample (4.75 nmol/L), generated a σ 321 
value between 2 and 3 (σ = 2.90). A result <3 indicates marginal performance and requires the 322 
application of multiple rules because of potential instability of the method. Examination of the 323 
inter-assay QCMLow data used to calculate this σ value did not reveal any outliers and, because 324 
the same batch of QCM was used throughout the study, it is proposed that this finding most 325 
likely represents instability of folate in the QCMLow matrix during storage rather than suboptimal 326 
performance of the method. Indeed, the CV and bias values for this sample were the highest 327 
generated in our study, and the same method for measuring folate in the low concentration serum 328 
samples (canine: 6 nmol/L, feline: 10 nmol/L) generated σ values indicating good to world class 329 
analytical performance. In addition, the lowest published folate concentration in clinically 330 
healthy animals using the Immulite assays is 11 nmol/L in dogs18,24 and 22 nmol/L in cats41,52; 331 
therefore, the marginal performance of FolateTosoh using QCMLow is unlikely to affect clinical 332 
decision-making. 333 
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Results of the method comparison for the cobalamin immunoassays demonstrated very 334 
high correlations between the 2 analyzers [r = 0.98 (canine), r = 0.97 (feline)] that were similar 335 
to those reported in another veterinary study comparing Tosoh and Immulite T4 and cortisol 336 
assays [T4 r = 0.94/0.97 (canine/feline), cortisol r = 0.97 (canine and feline)].26 337 
Examination of the Bland–Altman graph for cobalamin identified a large positive bias 338 
(canine: 75 pmol/L, feline: 184 pmol/L) and the presence of 7 outliers (2 canine, 5 feline). For 339 
these outliers, CobalaminTosoh values were higher than the CobalaminImmulite values, and the 340 
results were above the upper working limits of both assays (>1,480 pmol/L for Tosoh vs. >738 341 
pmol/L for Immulite) and/or above the Immulite reference intervals established at the external 342 
laboratory or reported in published studies (canine: <332 pmol/L, feline <1,110–1,240 343 
pmol/L).24,41,46 Regarding the feline cases, it has been proposed that, in cats with no history of 344 
vitamin supplementation, high serum cobalamin concentrations similar to those reported for the 345 
outliers may indicate underlying hepatic or neoplastic disease.46 We concluded that the degree of 346 
disagreement between the Tosoh and Immulite values would not have affected the clinical 347 
decision-making in these cases, because such high concentrations would be likely to prompt 348 
further investigations, regardless of the precise numerical value. Even so, the limits of agreement 349 
between the 2 methods were very wide, extending >630 pmol/L in dogs and 1,100 pmol/L in 350 
cats. We propose that the markedly different upper limits of the working ranges are the main 351 
reason for this finding. Indeed, 22 of the 68 canine and feline clinical samples generated >H 352 
values (Immulite: 16 samples, Tosoh: 6 samples). Given the lack of accurate quantification of 353 
these samples, the decision to arbitrarily allocate a +1 pmol/L above the upper limit of 354 
quantification may have led to inaccuracies and is likely to have created or accentuated 355 
proportional error for these samples with high cobalamin concentrations. Ideally, the samples 356 
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would have been diluted and re-analyzed to obtain a concentration within the assays’ working 357 
range. Because the Immulite assay was performed at an external laboratory and there were 358 
sample volume and financial restrictions, this was not done. Another approach could have been 359 
to exclude all samples with >H and <L results from the analysis, but this would have resulted in 360 
a narrower range of concentrations and a much lower number of paired values available for 361 
examining the agreement of canine and feline results. Indeed, repeated data analysis after 362 
exclusion of all >H and <L values generated 46 pairs of combined data with concentrations of 363 
58–1,350 pmol/L for CobalaminTosoh and 120–690 pmol/L for CobalaminImmulite. The correlation 364 
between the 2 assays was still very high (r = 0.97). Bland–Altman analysis revealed 2 outliers 365 
and a small positive bias (38 pmol/L), but the limits of agreement were still considered wide (–366 
69 to 145 pmol/L) extending over 194 pmol/L, and not indicative of good agreement. 367 
For folate measurement, correlations between the Immulite and Tosoh were high [r = 368 
0.88 (canine)] and very high [r = 0.92 (feline)] and similar to those reported in other studies 369 
comparing these analyzers [r = 0.94 (canine T4), r = 0.97 (feline T4), r = 0.97 (canine and feline 370 
cortisol), r = 0.88 (equine ACTH)].26,29 371 
Examination of the Bland–Altman graph for folate identified a negative bias (canine: –372 
1.3 nmol/L, feline: –4.5 nmol/L) and the presence of 3 outliers (2 canine, 1 feline). For two of 373 
these, the Tosoh gave lower folate values than the Immulite (canine: 26.5 vs. 44 nmol/L, feline: 374 
30.1 vs. 48.3 nmol/L) and for the other case, the Tosoh value was higher (canine: 39.5 vs. 26.3 375 
nmol/L). The limits of agreement between the 2 methods were very wide and extended over 22 376 
nmol/L in dogs and 21 nmol/L in cats. It is proposed that the markedly different upper limits of 377 
the working ranges are the main reason for this finding. Indeed, 8 of the 66 canine and feline 378 
clinical samples generated >H values, 4 with each instrument. As with cobalamin, given the lack 379 
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of accurate quantification of these samples, the decision to arbitrarily allocate a +1 nmol/L above 380 
the upper limit of quantification could have led to inaccuracies and accentuated the proportional 381 
error. Repeated data analysis after exclusion of all >H and <L values generated 61 pairs of 382 
combined data (canine: 36, feline: 25) with concentrations of 7.4–44.8 nmol/L and 6.7–51.7 383 
nmol/L for FolateTosoh and FolateImmulite, respectively. The correlation between the 2 assays was 384 
still high (r = 0.87). Bland–Altman analysis revealed 4 outliers and a small negative bias (–2.1 385 
nmol/L) but the limits of agreement remained wide (–12.8 to 8.6 nmol/L) extending over 21 386 
nmol/L, and indicative of poor agreement. 387 
We propose that the poor agreement between the Tosoh and Immulite methods may be 388 
explained by 2 differences: 1) inherent variations in methodology, for example pertaining to the 389 
monoclonal antibodies employed in each assay, or binding affinities of the porcine/bovine 390 
binding proteins to canine and feline cobalamin/folate,36 and 2) differences in sample storage 391 
conditions, which could have affected cobalamin and/or folate stability before sample analysis 392 
by the 2 instruments. Published studies into the stability of these analytes indicate that overall, 393 
cobalamin is a stable analyte at 4°C, room temperature, and frozen for 2 wk to >20 y.11,28,33,34 In 394 
contrast, storage studies on folate have produced variable results, with some indicating stability 395 
at 4°C for 1 wk and at 11°C for 10 d,33,34 whereas another study demonstrated a 50% decrease in 396 
concentrations after 8 d at room temperature or at –25°C.28 In our study, although all analyses 397 
took place on the same day or following storage for up to 24 h, the samples analyzed with the 398 
Tosoh were stored at 4°C (Diagnostic Laboratories), whereas those analyzed with the Immulite 399 
were exposed to different temperatures during transportation to the external laboratory before 400 
storage at 4°C. This may have had some effects on the results used for the comparison study. 401 
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A limitation of our study is the employment of a relatively low number of clinical 402 
samples for assessing the correlation and agreement of the results obtained from the 2 tested 403 
instruments. Because a minimum of 40 samples is recommended for such assessments,48 the 404 
number of samples was considered satisfactory for dogs (n = 39/37 for cobalamin/folate, 405 
respectively) but suboptimal for cats (n = 29). The latter is the result of the difficulty in recruiting 406 
samples with sufficient volume to perform all analyses. Studies using a higher number of patient 407 
samples would be worth performing in the future. 408 
The Tosoh immunoassays have good analytical performance and can be used to 409 
accurately measure cobalamin and folate in dogs and cats. The correlation between the Tosoh 410 
and Immulite is high; however, the agreement is poor, indicating that the results obtained by the 411 
2 analyzers cannot be used interchangeably and should therefore be interpreted using reference 412 
intervals established separately for each instrument. Further studies are required for the 413 
establishment of Tosoh-specific reference intervals, which will enable evaluation of the 414 
diagnostic performance and clinical utility of the Tosoh analyzer for the measurement of 415 
cobalamin and folate in dogs and cats. 416 
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Table 1. Spiking-recovery of cobalamin and folate from pooled canine and feline serum samples 536 















CPHigh + CPLow 878 882 100 34.3 34.4 100 
CPHigh + CPMedium 1,100 1,100 101 46.0 46.5 101 
CPMedium + CPLow 492 476 97 24.3 24.9 102 
FPHigh + FPLow 846 855 101 51.8 50.2 97 
FPHigh + FPMedium 1,130 1,190 106 58.1 55.8 96 
FPMedium + FPLow 463 439 95 24.8 25.2 102 
CPLow/FPLow, CPMedium/FPMedium, CPHigh/FPHigh = canine/feline serum pools with low, medium, 538 
and high concentrations of cobalamin or folate. 539 
540 
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Table 2. Cobalamin precision data using quality control material and canine and feline serum 541 
pools with low, medium, and high concentrations of cobalamin measured using the AIA-900 542 















QCMLow 194 6 2.8 269 11 4.0 
QCMMedium 532 14 2.6 655 21 3.2 
QCMHigh 685 17 2.4 891 32 3.6 
CPLow 137 6 4.1 145 9 6.0 
CPMedium 356 8 2.2 367 11 3.0 
CPHigh 741 22 3.0 775 26 3.3 
FPLow 91 9 9.3 102 7 6.8 
FPMedium 373 10 2.7 390 10 2.6 
FPHigh 755 14 1.8 795 26 3.3 
CPLow/FPLow, CPMedium/FPMedium, CPHigh/FPHigh = canine/feline serum pools with low, medium, 544 
and high concentrations of cobalamin; CV = coefficient of variation; QCMLow, QCMMedium, 545 
QCMHigh = quality control material with low, medium, and high concentrations of cobalamin; SD 546 
= standard deviation. 547 
548 
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Table 3. Folate precision data using quality control material and canine and feline serum pools 549 
with low, medium, and high concentrations of folate measured using theAIA-900 Tosoh 550 















QCMLow 3.0 0.3 9.1 4.8 0.4 8.1 
QCMMedium 19.0 0.3 2.9 12.3 0.8 6.1 
QCMHigh 23.1 0.7 3.1 31.4 2.0 6.4 
CPLow 6.3 0.3 5.2 6.0 0.3 5.4 
CPMedium 18.0 0.6 3.4 18.9 1.0 5.3 
CPHigh 28.0 0.5 1.8 27.6 1.1 4.1 
FPLow 9.2 0.2 2.7 9.9 0.3 3.4 
FPMedium 15.5 0.4 2.9 16.5 1.3 7.8 
FPHigh 42.6 0.7 1.5 41.7 2.2 5.3 
CPLow/FPLow, CPMedium/FPMedium, CPHigh/FPHigh = canine/feline serum pools with low, medium, 552 
and high concentrations of folate; CV = coefficient of variation; QCMLow, QCMMedium, QCMHigh 553 
= quality control material with low, medium, and high concentrations of folate; SD = standard 554 
deviation. 555 
556 
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Table 4. Total observable error and sigma (σ) values for the 3 levels of quality control material 557 
and canine and feline serum pools analyzed for cobalamin and folate using the AIA-900 Tosoh 558 
Bioscience analyzer immunoassays. 559 
Sample 
Cobalamin (TEa: 30%) Folate (TEa: 39%) 
TEobs (%) σ TEobs (%) σ 
QCMLow 13 6.1 31 2.9 
CPLow 17 4.1 26 4.4 
FPLow 19 3.6 22 7.0 
QCMMedium 7 9.3 20 5.1 
CPMedium 5 9.8 18 5.9 
FPMedium 4 11.5 23 4.0 
QCMHigh 9 7.8 21 4.8 
CPHigh 4 8.4 17 7.5 
FPHigh 4 8.4 19 5.7 
CPLow/FPLow, CPMedium/FPMedium, CPHigh/FPHigh = canine/feline serum pools with low, medium, 560 
and high concentrations of cobalamin or folate; QCMLow, QCMMedium, QCMHigh = quality control 561 
material with low, medium, and high concentrations of cobalamin or folate; TEa = total 562 
allowable error; TEobs = total observed error. Range of concentrations of above samples: 563 
CobalaminLow: 102–269 pmol/L, CobalaminMedium: 366–655 pmol/L, CobalaminHigh: 774–891 564 
pmol/L; FolateLow: 4.8–9.9 nmol/L, FolateMedium: 12.3–18.9 nmol/L, FolateHigh: 27.6–41.7 nmol/L 565 
566 
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Table 5. Median, range, and correlation results for cobalamin (pmol/L) and folate (nmol/L) 567 
measured in canine and feline samples using the AIA-900 Tosoh Bioscience analyzer 568 
immunoassays compared to the Immulite 2000 analyzer chemiluminescent assays.  569 
Analyte 
Tosoh Immulite 
r Median Range Median Range 
CobalaminCanine (n = 39) 328 76 to >1480 291 <111 to >738 0.98 
CobalaminFeline (n = 29) 552 58 to >1480 499 <111 to >738 0.97 
FolateCanine (n = 37) 22.9 9 to >45.4 23.8 6.7 to >54.4 0.88 
FolateFeline (n = 29) 30.1 9.4 to >45.4 34 9.8 to >54.4 0.92 
 570 
571 
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Table 6. Proportional error (slope), constant error (y-intercept), and bias for cobalamin (pmol/L) 572 
and folate (nmol/L) measured in canine and feline samples using the AIA-900 Tosoh Bioscience 573 
analyzer immunoassays compared to the Immulite 2000 analyzer chemiluminescent assays. 574 
Analyte 
Regression Bland–Altman 
Slope 95% CI y-intercept 95%CI Bias 95% CI 
No. of 
outliers 
CobalaminCanine (n = 39) 1.20 1–1.4 –18 –58 to 19 75 –239 to 390 2/39 
CobalaminFeline (n = 29) 1.70 1.3–2.3 –161 –416 to 49 184 –375 to 725 5/29 
FolateCanine (n = 37) 0.75 0.6–0.9 5 1.2 to 8.7 –1.3 –12 to 9 2/37 
FolateFeline (n = 29) 0.80 0.7–0.9 1.9 –2.9 to 6.7 –4.5 –15 to 6 1/29 
CI = confidence interval. 575 
576 
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Figure 1. Evaluation of linearity (dilutional parallelism): linear regression for measured vs. 577 
expected cobalamin and folate concentrations using the AIA-900 Tosoh Bioscience analyzer. 578 
A. Canine cobalamin (pmol/L); B. Feline cobalamin (pmol/L); C. Canine folate (nmol/L); D. 579 
Feline folate (nmol/L). 580 
Figure 2. Bland–Altman difference plots of the AIA-900 Tosoh Bioscience analyzer 581 
immunoassays compared to the Immulite 2000 analyzer chemiluminescent assays for A. 582 
canine cobalamin, B. feline cobalamin, C. canine folate, and D. feline folate. The dashed lines 583 
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